Clinical Trial

Effects of Functional Task Training on Muscle Health and Function in Older Adults With Sarcopenia

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 27, 2026 (before its estimated May 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Sarcopenia is a condition associated with aging that causes a loss of muscle mass, strength, and physical function. This decline limits the ability to perform basic daily activities and increases the risk of falls and dependency. The purpose of this clinical study is to determine the effects of a 12-week Functional Task Training (FTT) program on functional, structural, and physiological biomarkers in older adults with sarcopenia. FTT involves practicing everyday movements, such as standing up from a chair, climbing stairs, walking, and carrying objects. The study aims to answer the following question: Does Functional Task Training performed specifically in optimal muscle power zones offer greater improvements in aging biomarkers compared to standard Functional Task Training or traditional resistance training? The researchers hypothesize that while all exercise interventions will be beneficial, the FTT program focused on power zones will generate the greatest improvements in functional, physiological, and structural biomarkers in older adults with sarcopenia. To test this, 30 older adults (aged 60 and older) will be randomly assigned to one of three active groups for a 12-week period (2 days per week): an FTT group training in power zones, a standard FTT group, or a traditional resistance training group. All exercise groups will use a Functional Electromechanical Dynamometer (DEMF) to precisely measure and control the training loads.
Trial Details
NCT Number NCT07494916
Lead Sponsor Universidad de Granada
Conditions Sarcopenia, Aging, Physical Functional Performance, Muscle Weakness | Patient
Enrollment 30 participants
Start Date 2026-02-02
Primary Completion 2026-05-30 (estimated)
Study Completion 2027-07-02 (estimated)
Updated on ClinicalTrials.gov 2026-03-27